Table 2.
Study outcomes observed among rural and urban IBD cases between 1998/1999 and 2017/2018 fiscal years, n = yes (%)
| Full cohort | Crohn’s disease | Ulcerative colitis | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Study outcomes | Total (n = 5173) | Rural (n = 1544) | Urban (n = 3629) | Total (n = 2796) | Rural (n = 785) | Urban (n = 2011) | Total (n = 2377) | Rural (n = 759) | Urban (n = 1618) |
| Outpatient | |||||||||
| Gastroenterology visit | 4338 (83.9) | 1250 (81.0) | 3088 (85.1) | 2369 (84.7) | 654 (83.3) | 1715 (85.3) | 1969 (82.8) | 596 (78.5) | 1373 (84.9) |
| Lower endoscopy | 4509 (87.2) | 1356 (87.8) | 3153 (86.9) | 2255 (80.7) | 642 (81.8) | 1613 (802) | 2254 (94.8) | 714 (94.1) | 1540 (95.2) |
| Prescription claim of 5-ASA | 4121 (79.7) | 1282 (83.0) | 2839 (78.2) | 1912 (68.4) | 570 (72.6) | 1342 (66.7) | 2209 (92.9) | 712 (93.8) | 1497 (92.5) |
| Prescription claim of IMs | 1971 (38.1) | 554 (35.9) | 1417 (39.0) | 1336 (47.8) | 356 (45.4) | 980 (48.7) | 635 (26.7) | 198 (26.1) | 437 (27.0) |
| Prescription claim of biologics | 1252 (24.2) | 339 (22.0) | 913 (25.2) | 859 (30.7) | 219 (27.9) | 640 (31.8) | 393 (16.5) | 120 (15.8) | 273 (16.9) |
| Corticosteroid dependency | 216 (4.2) | 62 (4.0) | 154 (4.2) | 116 (4.1) | 33 (4.2) | 83 (4.1) | 100 (4.2) | 29 (3.8) | 71 (4.4) |
| Inpatient | |||||||||
| IBD-specific hospitalization | 2545 (49.2) | 839 (54.3) | 1706 (47.0) | 1498 (53.6) | 468 (59.6) | 1030 (51.2) | 1047 (44.0) | 371 (48.9) | 676 (41.8) |
| IBD-related hospitalization | 2761 (53.4) | 897 (58.1) | 1864 (51.7) | 1605 (57.4) | 491 (62.5) | 1114 (55.4) | 1156 (48.6) | 406 (53.5) | 750 (46.4) |
| Surgery for IBD | 1744 (33.7) | 526 (34.1) | 1218 (33.6) | 1016 (36.3) | 277 (35.3) | 739 (36.7) | 728 (30.6) | 249 (32.8) | 479 (29.6) |
5-ASA, 5-aminosalicylic acid; IM, immune modulators.